GMAB vs. UTHR: Genmab vs. United Therapeutics Stock Comparison
How do Genmab (GMAB) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Genmab (GMAB) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
United Therapeutics (UTHR) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | GMAB | UTHR |
|---|---|---|
| Name | Genmab A/S American Depositary Shares | United Therapeutics Corporation |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 32.98 billion USD | 23.94 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2009 | June 17, 1999 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GMAB | UTHR |
|---|---|---|
| Total Return (1Y) | 91.17% | 28.77% |
| Total Return (3Y, Annualized) | 20.70% | 37.63% |
| Total Return (5Y, Annualized) | 3.98% | 23.78% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GMAB | UTHR |
|---|---|---|
| Volatility (1Y, Annualized) | 45.68% | 35.00% |
| Beta (5Y) | 0.72 | 0.49 |
| Max Drawdown (5Y) | -61.79% | -33.00% |
| Avg. Volume (3M) | 4.09M | 694.55K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GMAB | UTHR |
|---|---|---|
| Sharpe Ratio (1Y) | 1.90 | 0.70 |
| Sortino Ratio (1Y) | 3.82 | 1.29 |
Profitability
ROE (TTM)
Both Genmab (GMAB) at 12.07% and United Therapeutics (UTHR) at 19.13% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.07%
- Max
- 109.18%
- GMAB
- 12.07%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.13%
- Max
- 109.18%
- UTHR
- 19.13%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
United Therapeutics (UTHR) at 38.61% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.97%
- Max
- 18.05%
- GMAB
- 16.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.61%
- UTHR
- 38.61%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Genmab (GMAB) at 37.15% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.15%
- Max
- 83.12%
- GMAB
- 37.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.99%
- Max
- 83.12%
- UTHR
- 28.99%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GMAB | UTHR |
|---|---|---|
| ROE (TTM) | 12.07% | 19.13% |
| ROA (TTM) | 8.24% | 10.91% |
| Net Margin (TTM) | 16.97% | 38.61% |
| Operating Margin (TTM) | 37.15% | 28.99% |
| Gross Margin (TTM) | 92.67% | 86.34% |
Growth
Revenue Growth
Both Genmab (GMAB) at 19.19% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Genmab (GMAB) at -9.23% and United Therapeutics (UTHR) at 13.07% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | GMAB | UTHR |
|---|---|---|
| Revenue Growth (YoY) | 19.19% | 10.61% |
| Revenue Growth (3Y CAGR) | 21.23% | 18.02% |
| EPS Growth (YoY) | -9.23% | 13.07% |
| EPS Growth (3Y CAGR) | 8.48% | 22.92% |
Financial Strength
Current Ratio (MRQ)
United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.45
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GMAB
- 2.45
- Min
- 0.10
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- UTHR
- 4.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Genmab (GMAB) carries debt-to-equity ratio of 0.82 against its industry range, while United Therapeutics (UTHR) reports no figure this period.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.82
- Max
- 1.42
- GMAB
- 0.82
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- UTHR
- --
Financial Strength Metrics
| Metric | GMAB | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 2.45 | 4.61 |
| Debt / Equity (MRQ) | 0.82 | -- |
| Net Debt / EBITDA | 2.45 | -1.53 |
Dividends
Dividend Yield (TTM)
Neither Genmab (GMAB) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Genmab (GMAB) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GMAB | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
United Therapeutics (UTHR) at 21.22 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.84
- Max
- 85.34
- GMAB
- 45.84
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.22
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- UTHR
- 21.22
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Genmab (GMAB) at 7.68 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.68
- Max
- 58.18
- Q3
- 25.77
- GMAB
- 7.68
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.51
- Max
- 58.18
- Q3
- 25.77
- UTHR
- 7.51
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Genmab (GMAB) at 5.36 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.36
- Max
- 13.53
- Q3
- 6.54
- GMAB
- 5.36
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.80
- Max
- 13.53
- Q3
- 6.54
- UTHR
- 3.80
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GMAB | UTHR |
|---|---|---|
| P/E Ratio (TTM) | 45.84 | 21.22 |
| P/S Ratio (TTM) | 7.68 | 7.51 |
| P/B Ratio (MRQ) | 5.36 | 3.80 |
| Free Cash Flow Yield (TTM) | 2.59% | 1.90% |